Premium
Nicotinamide reduces cyclooxygenase‐2 expression in HaCaT keratinocytes after ultraviolet‐B irradiation
Author(s) -
Monfrecola G.,
Di Caprio R.,
Balato N.,
Bevilacqua M. A.,
Iovine B.,
Lembo S.,
Balato A.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15338
Subject(s) - hacat , immunosuppression , nicotinamide , cancer research , cyclooxygenase , medicine , prostaglandin e2 , enzyme , prostaglandin , pharmacology , chemistry , dermatology , biochemistry , in vitro
In their interesting research letter, Chen et al. (2016 Apr 8. doi: 10.1111/bjd.14662)(1) described the protective effects of oral nicotinamide (NCT) for chemoprevention of non-melanoma skin cancers (NMSCs) in renal transplant recipients. We totally agree that NCT can represent a new opportunity for NMSC chemoprevention basing on its capability to preserve cellular energy reserve for ATP-dependent DNA repair as well as UV-induced immunosuppression.(2) Moreover, we hypothesize that one of the mechanisms through which NCT may act is by modulating the expression of cyclooxygenase (COX)-2, the rate-limiting enzyme in prostaglandin (PG) generation. This article is protected by copyright. All rights reserved